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Summary
The Trypanosoma brucei aminopurine transporter
P2/TbAT1 has long been implicated in the transport of,
and resistance to, the diamidine and melaminophenyl
arsenical classes of drugs that form the backbone
of the pharmacopoeia against African trypanoso-
miasis. Genetic alterations including deletions and
single nucleotide polymorphisms (SNPs) have been
observed in numerous strains and clinical isolates.
Here, we systematically investigate each reported
mutation and assess their effects on transporter func-
tion after expression in a tbat1−/− T. brucei line. Out of a
set of six reported SNPs from a reported ‘resistance
allele’, none significantly impaired sensitivity to pen-
tamidine, diminazene or melarsoprol, relative to the
TbAT1-WT allele, although several combinations, and
the deletion of the codon for residue F316, resulted in
highly significant impairment. These combinations of
SNPs, and ΔF316, also strongly impaired the uptake of
[3H]-adenosine and [3H]-diminazene, identical to the
tbat1−/− control. The TbAT1 protein model predicted
that residues F19, D140 and F316 interact with the
substrate of the transporter. Mutation of D140 to
alanine resulted in an inactive transporter, whereas the
mutation F19A produced a transporter with a slightly
increased affinity for [3H]-diminazene but reduced the
uptake rate. The results presented here validate earlier
hypotheses of drug binding motifs for TbAT1.
Introduction
African trypanosomiasis is a disease complex covering a
number of severe human and veterinary conditions,
caused by Trypanosoma brucei gambiense and T. b. rho-
desiense (human), and T. b. brucei, T. congolense and
T. vivax (veterinary) respectively. Despite the recent intro-
duction of nifurtimox-eflornithine combination therapy
(NECT) for late-stage gambiense sleeping sickness (Alirol
et al., 2013), melaminophenyl arsenicals (melarsoprol and
cymelarsan) and diamidines (pentamidine and dimina-
zene) continue to be used for all the African trypanosomi-
ases (Holmes et al., 2004; Delespaux and de Koning,
2007; Kennedy, 2013). Because these drugs have been
used for many decades, it is hardly surprising that resist-
ance to most of these drugs has become very problematic
(Barrett et al., 2011; Baker et al., 2013). Rates of resist-
ance of between 20% and 39% have been reported for
melarsoprol treatment in a wide variety of foci (Legros
et al., 1999; Brun et al., 2001; Moore and Richer, 2001;
Stanghellini and Josenando, 2001; Robays et al., 2008;
Mumba Ngoyi et al., 2010), and the ease of inducing
eflornithine resistance in a lab-setting (Vincent et al., 2010)
necessitated the identification of a partner drug to enable
combination therapy, resulting in NECT treatment (Priotto
et al., 2009). Drug resistance in African trypanosomes has
been strongly linked to alterations in various transporters,
including the amino acid transporter TbAAT6 for eflornith-
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ine (Vincent et al., 2010), P2/TbAT1 for arsenicals and
diminazene (Carter et al., 1999; de Koning et al., 2004)
and the High Affinity Pentamidine Transporter (HAPT1/
AQP2) for arsenicals and pentamidine (de Koning, 2001a;
Bridges et al., 2007; Munday et al., 2014).
The aminopurine transporter P2 was first linked to
arsenical resistance when it was observed that this trans-
port activity had disappeared from a T. b. brucei strain
adapted to sodium melarsen and that adenine and adeno-
sine could abrogate the effects of melaminophenyl arseni-
cals on trypanosomes (Carter and Fairlamb, 1993).
Cloning of the encoding gene, designated TbAT1, allowed
the identification of an allele from a melarsenoxide
cysteamine-resistant T. b. brucei clone that contained a
number of nucleotide differences relative to the drug-
sensitive paternal strain, resulting in six amino acid
changes: L71V, A178T, G181E, D239G, N286S and
L380P. Unlike the wild-type allele found in the sensitive
strain, this allele failed to sensitise yeast cells to melarsen
oxide (Mäser et al., 1999), and deletion of TbAT1 in
T. brucei caused reduced sensitivity to melaminophenyl
arsenicals and pentamidine, and a high level of resistance
to diminazene (Matovu et al., 2003). Moreover, these
drugs were shown to bind with high affinity to the P2
transporter (de Koning and Jarvis, 1999) and to conform
to the P2-transporter binding motif (de Koning, 2001b).
In a series of clinical T. b. gambiense isolates, mostly
from a focus in north-western Uganda with a high incidence
of melarsoprol treatment failure, 38 of 65 isolates con-
tained a TbAT1 allele that contained the same set of
mutations, except L380P, as well as a codon deletion for
residue F316, correlating significantly with relapse after
melarsoprol treatment (Matovu et al., 2001). However, it
has never been reported whether the full set of single
nucleotide polymorphisms (SNPs) is required for resist-
ance, or whether in fact only one of these might be respon-
sible for the phenotype. This is important as a restriction-
length polymorphism and an allele-specific polymerase
chain reaction (PCR) have been proposed as diagnostic
tools for the detection of melarsoprol resistance (Mäser
et al., 1999; Matovu et al., 2001; Nerima et al., 2007).
Furthermore, the mechanisms by which each of these
SNPs might cause resistance through changes in the
rate of TbAT1-mediated drug transport have remained
un-investigated. Here, we systematically introduce each
coding mutation that has been reported in a TbAT1 ‘resist-
ance allele’ and investigate their effects on the ability of the
gene to affect drug sensitivity and drug transport in a
tbat1−/− strain of T. brucei.
A TbAT1 protein model was created in order to predict
the location and the effects of the mutations mentioned
above in the transporter. In addition, the protein model
was used to suggest new amino acid residues predicted
to interact directly with the transported ligands. Two resi-
dues, F19 and D140, were identified in the binding pocket
and were mutated, separately and in combination, to
alanine residues, causing highly significant loss of dimi-
nazene transport and providing support for the proposed
TbAT1 protein structure.
Results and discussion
Expression of mutant TbAT1 alleles in T. brucei
strain B48
The TbAT1 mutant vectors were constructed by site
directed mutagenesis of pHDK44 (Munday et al., 2013),
the expression plasmid containing the control Wild-type
(WT) TbAT1 allele, and further by rearrangement of the
single mutation alleles to generate multiple mutation
alleles within one expression plasmid. They were verified
by Sanger sequencing, prior to transfection into the
T. brucei strain B48 (Bridges et al., 2007). Clones pro-
duced following transfection were screened by PCR for the
presence of the TbAT1 gene and to check that the plasmids
were linear and had integrated correctly prior to use for
drug resistance/uptake assays (data not shown).
Analysis of single nucleotide polymorphisms in reported
TbAT1 resistance alleles
It was previously shown that TbAT1, when expressed in
yeast, sensitises these cells to melarsen oxide (Mäser
et al., 1999). This gene, cloned from the melarsen-
sensitive T. b. brucei strain STIB777S, was also shown to
mediate transport of the diamidines diminazene and pen-
tamidine in yeast (de Koning et al., 2004). An alternative
sequence, TbAT1r, obtained from the same strain adapted
to melarsen oxide cysteamine (Cymelarsan®), STIB777R,
did not sensitise yeast to melaminophenyl arsenicals. The
resistance-associated allele contained six coding SNPs,
leading to the following mutations relative to the sensitive
reference gene: L71V, A178T, G181E, D239G, N268S and
L380P. The first five of these SNPs were then also reported
in isolates from multiple relapse patients from north-
western Uganda unsuccessfully treated with melarsoprol
(Matovu et al., 2001). In addition, these isolates contained
a further mutation, namely the deletion of the codon for
Phenylalanine 316. The same set of mutations was also
found in a melarsoprol-refractory T. b. rhodesiense isolate
from Southern Uganda, and in a T. b. gambiense isolate
from a melarsoprol relapse patient from Angola (Matovu
et al., 2001). In all, several studies showed a clear asso-
ciation of the mutant alleles with melarsoprol resistance,
although the correlation was not absolute (Mäser et al.,
2001; Matovu et al., 2001; Kazibwe et al., 2009). However,
it has never been reported which, or which combination, of
the observed mutations was responsible for the apparent
impairment of drug transport.
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We have therefore introduced each of the six STIB777R
mutations and the F316 deletion separately in the refer-
ence sequence and expressed the mutant alleles in the
multi-drug resistance T. b. brucei line B48, which was
derived from the tbat1 knockout strain tbat1−/− (Matovu
et al., 2003; Bridges et al., 2007) and assessed whether
this affected the susceptibility phenotype to melami-
nophenyl arsenicals (cymelarsan) and diamidines (penta-
midine, diminazene aceturate); phenylarsine oxide (PAO)
was used as a control trypanocide that does not depend
on the presence of the TbAT1 transporter (Carter and
Fairlamb, 1993; Bridges et al., 2007). The EC50 values
obtained for all four drugs were compared with those for
the same cell line transfected with an ‘empty vector’
without insert (B48 + EV; drug-resistant control) as well as
with the same cells transfected with the wild-type allele of
TbAT1 (B48 + TbAT1; drug-sensitive control) and the
parental strain Lister 427 (WT). As shown in Fig. 1, all of
the individual mutation alleles displayed at least partial
uptake activity for the cymelarsan and the diamidines,
leading to highly significant susceptibility to these com-
pounds, but not to PAO, relative to B48 + EV [P < 0.001;
one-way analysis of variance (ANOVA)].
None of the STIB777R SNPs identified by Mäser et al.
(1999) significantly changed susceptibility to the test drugs
compared with expression of the wild-type TbAT1 trans-
porter (B48 + TbAT1), although expression of TbAT1L380P
tended to increase the susceptibility of the B48 cells slightly
less than the wild-type allele (Fig. 1). The deletion mutation
Δ(F316) identified in clinical isolates, however, appeared
to almost completely abolish drug transport activity: its
expression increased drug susceptibility only slightly, rela-
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Fig. 1. Effective concentration 50% (EC50) values for four trypanocidal drugs as determined using the Alamar Blue fluorescence assay. The
strains tested were all derived from T. b. brucei s427 wild-type (WT); B48 is a multidrug-resistant strain lacking the genes for the TbAT1 and
TbAQP2 drug transporters (Munday et al., 2014). B48 + EV is the resistant control of B48 transfected with the empty vector (EV) pHD1336
(Biebinger et al., 1997). All the variants of TbAT1 including the wild-type copy (B48 + TbAT1) were expressed in B48 using this vector (Munday
et al., 2013). Mutations (Mut) 1–6 are as listed in the box; Δ(F316) is the TbAT1 allele from which the codon for Phe316 was deleted. The
dotted line running across each panel denotes the EC50 value of the B48 + EV control for each drug. Statistical significance was determined
using a one-way ANOVA relative to B48 + EV, in GraphPad Prism 5.0. **, P < 0.01; ***, P < 0.001. Data shown are the average and SEM of at
least five independent determinations.
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tive to B48 + EV, although still significantly. However, the
line expressing the Δ(F316) allele was significantly more
resistant to the test drugs, except PAO, than B48 + TbAT1
(P < 0.001).
As none of the STIB777R mutations individually
appeared to give rise to a significant loss of drug transport
activity, we investigated whether combinations of these
SNPs together explain the lack of drug susceptibility
reported by the STIB777R resistance allele (Mäser et al.,
1999). Expression of a TbAT1 allele with mutations 5
(N286S) and 6 (L380P) together created a trypanosome
with an intermediate susceptibility phenotype that was
significantly more resistant than B48 + TbAT1 but signifi-
cantly more sensitive than B40 + EV (P < 0.001; Fig. 1).
Expression of alleles bearing mutations 1–3 (L71V /A178T
/ G181E), 4–6 (D239G / N286S / L380P) or all six mutations
were completely resistant to diamidines and cymelarsan.
Transport of adenosine and diminazene by TbAT1
transporters with STIB777R mutations
In order to verify that the drug susceptibility phenotypes
described above are indeed linked to similar changes
in transporter activity, we measured transport rates for
0.1 μM [3H]-adenosine and for 0.1 μM [3H]-diminazene.
Adenosine uptake was conducted in the presence of 1 mM
inosine in order to block transport through the P1-type
nucleoside transporters, as described (de Koning and
Jarvis, 1999; Al-Salabi et al., 2007).
The mutations had virtually identical effects on transport
of adenosine and diminazene (Fig. 2), suggesting that the
general functioning of the transporter was affected rather
than its specificity changed to disable the transport of
diamidines while retaining its physiological function. Muta-
tion 6 (L380P) alone caused only a slight decrease in
adenosine and diminazene transport rates, which was
significant for adenosine (P < 0.05; paired t-test). Trans-
port rates were further reduced in the mut5 + 6 double
mutant (P < 0.01) but still remained above the level of the
Mut4-6 triple mutant (Fig. 2), indicating that the activity was
not completely abrogated. For alleles with mutations 1–3,
4–6 and 1–6, transport of either substrate was barely
detectable and not significantly different from the B48 + EV
control while highly significantly different from B48 +
TbAT1 (P < 0.01, paired t-test; n = 3). Similarly, dimina-
zene uptake in Δ(F316) was barely detectable (Fig. 2B).
Thus, the transport results match the drug sensitisation
profiles very well.
We next investigated whether the transport rates were
reduced because of reduced substrate affinity (Km), or
because of impaired transport efficiency, expressed as
Vmax/Km. To this end, transport of 0.1 μM [3H]-adenosine
was measured in the presence of various concentrations of
unlabelled adenosine (Fig. 3), using B48 clones express-
ing either TbAT-WT, TbAT1 mutation 6 alone or mutations
5 and 6. No attempt to obtain kinetic parameters for the
other strains (+Mut4-6, +Mut1-6, +Mut1-3) was undertaken
as the TbAT1 transport activity could not be detected in
these clones (Fig. 2). It was clear that no change had
occurred in the substrate affinity, as the dose-dependency
of inhibition with unlabelled adenosine was unchanged
(Fig. 3). However, the rate of uptake was again observed to
be substantially lower in the mutant lines, and the conver-
sion of the data to Michaelis-Menten plots (Fig. 3, inset),
clearly shows that it is the Vmax rather than the Km that is
affected by the mutations; this could be either the result of
reduced translocation rates by the mutant transporters, or
due to reduced numbers of the mutant transporters in the
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Fig. 2. Transport of (A) 0.1 μM [3H]-adenosine or (B) 0.1 μM [3H]-diminazene aceturate by T. b. brucei B48 transfected with empty vector
pHD1336 (B48 + EV) expressing either the wild-type TbAT1 allele or a mutant TbAT1 allele as listed in Fig. 1. Incubation times were 30 s or
60 s for adenosine or diminazene transport respectively. All bars are the average of three independent experiments and error bars represent
SEM; statistical significance was calculated relative to TbAT1WT (unless specifically indicated) using a paired Student’s t-test: *, P < 0.05;
**, P < 0.02; ***, P < 0.01.
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plasma membrane. Table 1 gives the average values from
four independent experiments, showing significant differ-
ences of Vmax but not Km values for both mutants.
Modelling the mutants
In order to rationalise the effect of the mutations described
above, a protein model of the TbAT1 transporter was
constructed using ROBETTA as described in the method
section. The top-ranked model (model 1) produced by
ROBETTAwas structurally aligned with the LdNT1.1 model
published by Valdes et al. (2009; 2012). This structural
alignment is shown in Fig. S1 in the supplementary infor-
mation section. It is interesting to note that the two protein
model structures can be easily structural aligned despite
the fact they were created using different methodologies
and have dissimilar protein sequences. In fact Valdes et al.
built the LdNT1.1 model using structure fragments gener-
ated by the standard ROSETTA fragment server in combi-
nation with a secondary structure prediction method
(Valdes et al., 2009); the TbAT1 protein model described
in the present study was instead created using partial
threaded protein models using two different crystal struc-
ture templates. This seems to confirm that, despite the
limited sequence similarity (amino acid sequence 29%
identity; 50% similarity), these two structurally related pro-
teins are expected to recognise and transport adenosine in
a similar way, in agreement with the observation that, in
evolution, structure is more conserved than sequence
(Holm and Sander, 1996). Figure 4 displays the positions
of those residues positioned within the transmembrane
(TM)-helices that were mutated in the present study. The
mutations L71V, L380P and the deletion of F316 have been
putatively linked in the literature to melarsoprol resistance
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Fig. 3. Transport of 0.1 μM [3H]-adenosine
by B48 cells expressing various TbAT1 alleles
as indicated (numbering as in Fig. 1), in the
presence or absence of various
concentrations of unlabelled adenosine. Main
figure: experiment performed in triplicate with
unlabelled adenosine as inhibitor, resulting in
sigmoid competition curves. Inset: conversion
of the same experiment to Michaelis-Menten
saturation plots displaying total adenosine
uptake against adenosine concentration. The
experiment depicted is representative of four
independent experiments, which are
summarised in Table 1.
Table 1. Effects of mutations in TbAT1 amino acids 286 and 380 on
kinetic parameters of adenosine transport.
TbAT1-WT TbAT1L380P TbAT1N286S+L380P
Km (μM) 0.82 ± 0.25 0.69 ± 0.13 1.02 ± 0.29
Vmax (pmol(107
cells)−1 s−1)
0.35 ± 0.07 0.12 ± 0.01a 0.027 ± 0.008b
Vmax/Km 0.43 0.17 0.026
Vmax and Km values for TbAT1-mediated [3H]-adenosine transport
were determined in the presence of 1 mM inosine, using 0.1 μM
radiolabel and 10 s incubations to determine the initial rates of trans-
port. The data shown are the average and standard error of the mean
of four independent experiments, each performed in triplicate, in
which the parameters for all three strains was determined in parallel,
using the same solutions and conditions.
a. P < 0.02.
b. P < 0.01 (unpaired Student’s t-test, relative to the wild-type allele
of TbAT1).
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Fig. 4. TbAT1 model created using
ROBETTA. Residues whose mutation is
described in this study are displayed in
space-filling models. The ligand adenosine is
shown in green carbon atoms as docked in
the TbAT1 protein model. Extracellular and
intracellular intra TM-helical loops were not
modelled and are therefore not shown.
Helices are indicated by rigid cylinders. Both
top view (A; extracellular side) and side view
(B) are shown. TM-domains are labelled with
roman numerals. The image was created
using PyMol version 1.50.04, Schrödinger.
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(Mäser et al., 1999) but were never mapped in a TbAT1
protein model. The model suggests that F316 is in close
proximity with the ligand, whereas L71 and L380 are
located far from the substrate translocation channel
(Fig. 4). A deletion of F316 is expected to have an impor-
tant effect on the binding and transport of the substrate –
not just because it is expected to contribute to substrate
binding but also because the deletion changes the position
and orientation of the subsequent amino acid residues in
the TM-helix. The experimental results seem in agreement
with this prediction showing that the F316 deletion is
substantially impaired in the uptake of different substrates
(Figs 1 and 2). Clearly, the mutation L380P is predicted to
have a detrimental effect for the folding of the TM-helix
because the proline residue cannot donate an intra-helical
amide hydrogen bond (having no amide hydrogen), and
also because its side-chain interferes sterically with the
backbone of the same helix (Richardson, 1981). The
mutants A178T, G181E, D239G, N286S also published in
the literature (Mäser et al., 1999) are located in intracellular
or extracellular loops that are notoriously difficult to model
and are not displayed in Fig. 4 so it is difficult to understand
the effect of these mutations using molecular modelling
techniques.
Two new mutations were introduced in order to test the
predictions of the protein model with respect to ligand
binding: F19A and D140A (Figs 4–6). The structural align-
ment of TbAT1 and LdNT1 (Fig. 5) suggested a hypothesis
for the residues involved in the recognition and transport of
adenosine. The knowledge of the key residues affecting
substrate specificity and/or adenosine uptake activity in
LdNT1.1 (Valdes et al., 2009) helped to study in silico the
protein–substrate interactions in TbAT1. F316, F19 and
D140 are in proximity to the docked adenosine in a pocket
located within the channel, near the extracellular side
(Figs 4–6). These residues are structurally aligned with
F341, M40 and E157 (in LdNT1.1) respectively (Fig. 5).
Mutations of each of these three residues in LdNT1.1 are
known to affect substrate specificity or result in a loss of
adenosine uptake activity (Valdes et al., 2009) suggesting
that these residues play a key role in the binding and
transport of the substrate. In particular, the side-chain of
D140 of TbAT1 is predicted to give a bidentate interaction
with the ligand accepting two hydrogen bonds: from (i) the
amino group of adenosine and (ii) nitrogen-1 of the purine
ring (Fig. 6). The nitrogen-1 in the adenine ring is in fact
protonated at physiological pH as shown experimentally
(Christensen et al., 1970; Zimmer and Biltonen, 1972;
Major et al., 2002) and using quantum-mechanical calcu-
lations (Turecek and Chen, 2005). Valdes et al. reported
that the mutation E157 to aspartate or glutamine caused a
change in substrate specificity or a loss of more than 95%
of adenosine uptake respectively (Valdes et al., 2009). Our
study suggests that D140 in TbAT1 (and therefore also
E157 in LdNT1.1) is predicted to accept hydrogen bonds
from the purine ring (Fig. 6). D140 is predicted to give a
D140
(E157)
F19
(M40)
F316
(F341)
Fig. 5. Structural overlay between the LdNT1.1 model published
by Valdes et al. (2009; 2012) – in brown; and the TbAT1 model
obtained created by ROBETTA – in cyan. The extracellular side is
shown. The ligand adenosine docked in the TbAT1 protein model is
shown in green carbon atoms. Helices are indicated by rigid
cylinders. The extracellular and intracellular TM-helical loops were
not modelled and are therefore not shown. The TbAT1 residue
numbering is used, with the LdNT1.1 residues in brackets. The
image was created using PyMol version 1.50.04, Schrödinger.
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F316
F19
Fig. 6. Overlay between the predicted binding poses of adenosine
(green carbon atoms) and diminazene (yellow carbon atoms) in the
TbAT1 model obtained created by ROBETTA (colored in cyan).
Residues F19, D140 and F316 are displayed in space-filling
models. Helices are indicated by rigid cylinders. The hydrogen
bonds between the side-chain carboxylate group of Asp140 and (i)
the amino group and (ii) the protonated nitrogen-1 of the adenosine
ring are shown in dashed blue lines. The image was created using
PyMol version 1.50.04, Schrödinger.
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similar bidentate interaction with the melamine moiety of
cymelarsan or the amidine group of pentamidine and dimi-
nazene (Figs 6 and 7A–C). Interestingly, phenylarsine
oxide does not contain any hydrogen bond donor function-
ality, suggesting there would be no interaction with D140
(Fig. 7D), which is consistent with the previously reported
TbAT1-independent uptake of this compound (Carter
and Fairlamb, 1993; Bridges et al., 2007). F19 in TbAT1 is
instead structurally aligned with M40 in LdNT1.1. Both
phenylalanine and methionine are hydrophobic residues,
and it has been reported that the latter residue is also
capable of π-interaction similarly to aromatic residues
(Tatko and Waters, 2004). The proposed binding mode of
adenosine to TbAT1 presented in this study is in agreement
with previous studies published in the literature that
suggest the presence of: (i) hydrogen-bonds with the
nitrogen-1 and the amino-group of the adenine ring; and (ii)
π-stacking with the adenine aromatic system (de Koning
and Jarvis, 1999; de Koning et al., 2005; Lüscher et al.,
2007). Our model suggests that the two hydrogen bonds
mentioned above are accepted by the carboxylate group of
D140, whereas the π-stacking could be given by F19
and/or F316 that are predicted to be located in proximity of
the ligand.
Drug sensitivity profile of predicted binding
pocket mutants
The susceptibility of these mutants to diamidines and
arsenicals is displayed in Fig. 8. The mutant alleles F19A
and D140A had little effect on the susceptibility to penta-
midine, diminazene and cymelarsan, relative to the
B48 + EV line, whereas the cells expressing the wild-type
TbAT1 allele were sensitised to all; PAO had an identical
effect on all cells lines. The F19A mutant was somewhat
more susceptible than the empty vector control (P < 0.001;
one-way ANOVA), as well as much less susceptible than
the TbAT1-WT control (P < 0.001). The D140A mutation,
however, appeared to produce a completely inactive
transporter, as susceptibility of the B48 + EV and B48 +
TbAT1D140A cell lines to the test drugs was not significantly
different. Combining both mutations resulted in an equally
inactive transporter.
Transport of diminazene by TbAT1F19A
The rate of 0.1 μM [3H]-diminazene transport was signi-
ficantly reduced in cells expressing the TbAT1F19A,
TbAT1D140A and TbAT1F19A+D140A mutations, when compared
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Fig. 7. Schematic model for the interactions between TbAT1 ligands adenosine (A), diminazene (B) and melarsoprol (C) with the critical
amino acid residues in the TbAT1 binding pocket; Frame (D) shows the putative interaction of phenylarsine oxide with the binding pocket.
Hydrogen bonds are depicted as dotted lines. The image was created using ChemDraw Pro 10.0, CambridgeSoft.
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with cells expressing TbAT1-WT (all P < 0.001, n = 4). Of
the three mutant lines, only diminazene uptake in the
B48 + TbAT1F19A line was significantly faster than B48 +
EV (P < 0.01; Fig. 9A); there was no significant difference
in diminazene uptake by B48 + EV and B48 + TbAT1D140A
or B48 + TbAT1F19A+D140A. As with the STIB777R-derived
mutants that still displayed quantifiable transport rates, we
determined the Km and Vmax values for the F19A mutant
(Fig. 9B). Surprisingly both parameters were significantly
lower compared with the wild-type TbAT1 allele (Table 2).
Although this results in a transporter with a threefold higher
affinity for diminazene, the actual rate of transport was
much reduced, possibly because of restrictions in the
required conformational change, or the proton symport on
which the T. brucei purine transporters are dependent (de
Koning and Jarvis, 1997a,b; de Koning et al., 1998); addi-
tionally, it is expected that the stronger binding by the
mutant transporter might result in a reduced off-rate for the
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Fig. 8. EC50 values obtained by the Alamar
Blue test for strains expressing mutant alleles
of TbAT1. Bars represent the average and
SEM of six independent experiments.
Statistical significance was determined by a
one-way ANOVA, compared to B48 + EV
except where specifically indicated.
Table 2. Effects of the F19A mutation on kinetic parameters of
diminazene transport.
TbAT1-WT TbAT1F19A
Km (μM) 0.64 ± 0.15 0.21 ± 0.03a
Vmax (pmol(107 cells)−1 s−1) 0.040 ± 0.006 0.007 ± 0.002b
Vmax/Km 0.062 0.034
Vmax and Km values for TbAT1-mediated [3H]-diminazene transport
was determined using 0.1 μM radiolabel and 60 s incubations to
determine the initial rates of transport. The data shown are the
average and standard error of the mean of four independent experi-
ments, each performed in triplicate, in which the parameters for both
strains was determined in parallel, using the same solutions and
conditions.
a. P < 0.02.
b. P < 0.01 (unpaired Student’s t-test, relative to the wild-type allele
of TbAT1).
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release of the substrate into the cell. However, the overall
rate of transport by the mutant transporter is dependent on
both the translocation rate of each transport protein (cata-
lytic activity) and the number of such proteins in the plasma
membrane, either or both of which might be affected by the
mutation. In summary, our results show that F19, D140 and
F316 (Fig. 6) are key residues in the protein channel
responsible for the interaction with substrates and this is in
agreement with the model proposed.
The results presented here provide new insights into
the molecular causes of drug resistance in African
trypanosomes of the brucei group. Remarkably, no
individual SNPs previously reported in resistance-
associated TbAT1 alleles had a significant effect on drug
sensitivity in T. brucei, as the introduction of a TbAT1
allele with any one of those SNPs sensitised a tbat1−/−
strain in the same way as the wild-type TbAT1 allele.
Only the mutation L380P, which was not present in the
resistance alleles isolated from the melarsoprol-relapse
patients in Uganda and Angola (Matovu et al., 2001),
appeared to affect drug sensitivity although this did not
reach statistical significance. However, the combination
of two or three, or all six, of these mutations did render
the drug transport activity mostly (N286S/L380P), or
completely, defective. Importantly, the single mutation
ΔF316 also resulted in an allele that confers partial
resistance to diamidines and cymelarsan and was
unable to transport [3H]-diminazene.
The results are thus in complete agreement with the
reports that associate this set of mutations with drug resist-
ance and melarsoprol treatment failure (Mäser et al., 1999;
Matovu et al., 2001), although we must emphasise that (i)
not all mutations in these alleles are required in order to
have complete loss of drug transport through TbAT1 and
(ii) other mutations may similarly cause loss of TbAT1
function. For instance, we have previously reported on
three laboratory-adapted MPXR strains (one each of
T. b. brucei, T. b. gambiense and T. equiperdum) that did
not introduce any of the TbAT1 mutations here described
but either lost the complete TbAT1 open reading frame or
TbAT1 expression (Stewart et al., 2010). Similarly, the
T. b. rhodesiense strain STIB900 had lost the TbAT1 ORF
after in vitro adaptation to melarsoprol (Bernhard et al.,
2007), and a new mutant TbAT1 was found after adaptation
to pentamidine (Munday et al., 2014). Yet, the presence of
an ‘TbAT1 resistance allele’ identical to that reported
by Matovu et al. (2001), including the same set of
silent mutations, was recently confirmed in two MPXR
T. b. brucei isolates from Somalia and an MPXR T. b. rho-
desiense isolate from Uganda (Graf et al., 2013); the only
other TbAT1 mutation in a field isolate was a tri-nucleotide
deletion in two isolates from the Democratic Republic of
Congo, TbAT1-Δ516–518, which introduces one SNP and
deletes an amino acid from the fifth predicted TM domain
(Pyana Pati et al., 2014). We conclude that the mutations
here investigated are stable in trypanosome populations in
Eastern Africa and highly relevant to drug resistance in the
treatment of livestock with diminazene and of late-stage
rhodesiense sleeping sickness with melarsoprol (the only
treatment available (Delespaux and de Koning, 2007)).
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Fig. 9. Uptake of 0.1 μM [3H]-diminazene is significantly reduced following reintroduction of mutated TbAT1 relative to the wild type TbAT1.
A. Transport of diminazene was assessed in each strain. Bars show mean rate of transport ± SEM at 1 min when normalised for background,
n = 4. * = P < 0.05, ** = P < 0.01, *** = P < 0.001 (one-way ANOVA and Dunnett’s test), compared against B48 + EV, unless otherwise
indicated.
B. Inhibition (main figure) and saturation plot (inset) of 0.1 μM [3H]-diminazene over 60 s in the presence or absence of various concentrations
of unlabelled diminazene as indicated. The experiment show was performed in triplicate and representative of four independent experiments,
which are summarised in Table 2.
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A protein model of TbAT1 was built and then structurally
aligned with the LdNT1.1 protein model validated by
mutagenesis by Valdes et al. (2009). This suggests that
four of the SNPs (A178T, G181E, D239G and N286S) are
located in extracellular or intracellular loops and that the
other two (L71V and L380P) are located in TM domains
remote from the predicted binding site. Thus, the likely
rationale for the observed phenotypes is that none of the
SNPs is directly involved in ligand binding and that it takes
several such mutations to affect the structure to the point
of destroying the drug transport activity. The reason that
L380P had an effect on the transport, when compared
with the other single SNP mutants, is most likely due to
the introduction of a proline residue (a residue known to
destabilise α-helices) in the middle of a TM-helix domain.
Visual inspection showed that the most favourable
energy-minimised pose of diminazene displayed a strong
bidentate interaction between the guanidine group of this
ligand and the carboxylate group of Asp140 (a residue
known to also play a key role in substrate recognition
in LdNT1.1 (Valdes et al., 2009). These are well-known,
strong hydrogen-bond interactions, whose energetics
have been investigated in detail using experimental
methods (Linton and Hamilton, 1999). Interestingly, the
latter study shows that the bidentate interaction between
a guanidine group and a carboxylate is associated with
an experimental enthalpic change of −3.6 kcal mol−1
(−15.1 KJ mol−1). Collar et al. (2009) show, based on
ligand binding studies, that the amino group and the nitro-
gen atom 1 of adenosine (the atoms that we predict to be
involved in this bidentate interaction) is predicted to con-
tribute for a total of 7.7 + 8.2 = 15.9 KJ mol−1 to the inter-
actions of adenosine with TbAT1, which is remarkably
similar to the experimental enthalpic contribution of a
bidentate H-bond such as with Asp140.
When we introduced mutations in any of the residues
that our model predicted to be directly involved in ligand
binding (F19, D140 and F316), the result was a highly
significant or a complete loss of drug transport ability.
Particularly, the mutation of aspartate 140 to alanine
resulted in a completely non-functional transporter with
respect to drug sensitivity and diminazene transport. This
is not surprising as our previously published results (de
Koning and Jarvis, 1999; Collar et al., 2009) clearly iden-
tified a –N = C-NH2 motif as essential for ligand binding by
TbAT1. This motif corresponds to the protonated purinic
nitrogen N1 and the amine group in position 6 of adeno-
sine, the amidine group of pentamidine and other diami-
dines, such as diminazene and DB75, and the melamine
ring of melarsoprol and cymelarsan (de Koning et al.,
2005). Our model suggests that these hydrogen bonds
are established with the side-chain carboxylate group of
aspartate residue at position 140. The previous studies of
the P2 ligand-binding motif also predicted an important
contribution from π-orbital interactions between the purine
ring (or benzamidine, or melaminophenyl moieties) and
aromatic residues in the binding pocket, which we here
identify as F19 and F316.
We conclude that the TbAT1 protein model described
here is consistent with the functional analysis presented
in the current manuscript and with the extensive ligand
binding and transport studies conducted on this impor-
tant determinant of trypanosomal drug sensitivity and
resistance.
Experimental procedures
Trypanosome strains and culturing
Bloodstream-form T. b. brucei strain B48 and its derivatives
were maintained as previously described (Teka et al., 2011).
The B48 strain is derived from the Lister 427 strain, but lacks
the T. brucei TbAT-1 gene and lost the high affinity pentami-
dine transport activity (Bridges et al., 2007) as a result of a
genomic rearrangement in the TbAQP2-AQP3 locus (Baker
et al., 2012).
Plasmid construction and transfection
All six mutations in the T. brucei P2 aminopurine transporter
(TbAT1) identified by Matovu et al. (2001) were introduced
into pHDK44 (Munday et al., 2013), which was based on
pHD1336 (Biebinger et al., 1997), by site directed mutagen-
esis, using the QuikChange II kit (Agilent, Santa Clara, CA,
USA), following the manufacturer’s instructions.
The following primers were used to generate TbAT1 muta-
tions: for L71V, primers HDK347 & 348, producing plasmid
pHDK51; for L380P, primers HDK349 & 350, plasmid pHDK52;
forA178T, primers HDK351 & 352, giving plasmid pHDK53; for
G181E, primers HDK353 & 354, giving plasmid pHDK54; for
D239G, primers HDK355 & 356, to produce pHDK55 and
for the mutation N286S, primers HDK357 & 358, giving
plasmid pHDK56 (all primer details given in Supplementary
Table S1).
Combinations of these individual mutations were con-
structed by either further site directed mutagenesis or by
digestion and ligation of relevant fragments from the indi-
vidual plasmids. The plasmid containing TbAT1 with both the
N286S and L380P mutations was made by digestion of the
two single mutation plasmids using SacII. The dropout from
pHDK55 (N286S) was ligated into the backbone of pHDK56
(L380P), to give plasmid pHDK58. Following this, the further
mutation, D239G, was inserted into plasmid pHDK58 by site
directed mutagenesis, using primers HDK353 & 354, to give
plasmid pHDK59. Plasmid pHDK57, containing mutations
A178T and G181E, was generated by site directed mutage-
nesis of plasmid pHD52, using primers HDK359 & 360. The
mutation L71V was further added to give plasmid pHDK61,
by digestion of pHDK51 and pHDK57 with MfeI and NotI.
Finally, all six mutations were combined into one plasmid by
digestion and re-combination of pHDK59 and pHDK61 using
BspMI and AlwNI, to give plasmid pHDK62.
The deletion of codon F316 (also from Matovu et al., 2001)
was completed by site directed mutagenesis of pHDK44
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using the primers HDK469 & 470, giving plasmid pHDK64.
The two active site mutations were also introduced by site
directed mutagenesis, using primers HDK483 & 484 for
mutation F19A, giving plasmid pHDK65 and the primers
HDK485 & 486 for D140A, to produce plasmid pHDK66.
All plasmids were checked by Sanger Sequencing (Source
BioScience, Nottingham, UK) for the presence of the correct
mutation(s) and linearised with NotI prior to transfection. B48
parasites were washed into Human T Cell Solution for trans-
fection of the desired cassette with an Amaxa Nucleofector as
described (Burkard et al., 2007). Transfectants were grown
and cloned out, by limiting dilution, in standard HMI-11
(Hirumi and Hirumi, 1989) containing 5 μg ml−1 blasticidin S.
Correct integration of the expression cassettes was analysed
by PCR.
Drug sensitivity assays
Drug sensitivities were assessed using the dye resazurin
(Alamar blue) using a protocol adapted from Räz et al.
(1997), as described (Gould et al., 2008; 2013). Briefly, drugs
were serially diluted in 100 μl of complete HMI-11 media
across two rows of a 96 well plate. Cultures of bloodstream-
form trypanosomes were diluted in complete HMI-11, and
100 μl was added to all wells. Plates were incubated for 48 h
at 37°C/5% CO2, prior to the addition of 20 μl of 5 mM resa-
zurin sodium salt (Sigma-Aldrich) in PBS, pH7.4. Plates were
incubated for a further 24 h in the same conditions, before
fluorescence was measured using a FLUOstar Optima
fluorimeter (BMG Labtech). The 50% effective concentrations
(EC50) were calculated using the equation for a sigmoidal
curve with variable slope of Prism 5 (GraphPad). Experi-
ments were performed independently at least five times.
Transport assays
Uptake assays of [3H]-diminazene and [3H]-adenosine were
performed exactly as described (Wallace et al., 2002; Natto
et al., 2005). Briefly, trypanosomes from late-log phase cul-
tures were washed into assay buffer (AB; 33 mM HEPES,
98 mM NaCl, 4.6 mM KCl, 0.55 mM CaCl2, 0.07 mM MgSO4,
5.8 mM NaH2PO4, 0.3 mM MgCl2, 23 mM NaHCO3, 14 mM
glucose, pH 7.3) and resuspended at 108 cells ml−1. One
hundred microlitres of cell suspension was incubated
with either [Ring-3H]-diminazene aceturate (Perkin Elmer,
60.7 Ci mmol−1), or [2,8-3H]-adenosine (American Radiola-
beled Chemicals Inc, 40 Ci mmol−1), in the presence or
absence of unlabeled substrate or other competitive inhibitors.
Incubations were stopped by centrifugation through oil
(13 000× g; 1 min). The cell pellet was transferred to a scintil-
lation tube, and radioactivity was determined by liquid scintil-
lation counting. The results were plotted to equations for linear
or non-linear regression using Prism 5 (GraphPad) after cor-
rection for non-specific association of radiolabel with the
pellet, as described (Wallace et al., 2002).
Creation of the protein model and docking
The protein sequence of the TbAT1 was obtained from direct
Sanger sequencing of the gene in Lister 427 parasites. Five
different protein models of TbAT1 were created using
ROBETTA (http://www.robetta.bakerlab.org). This full-chain
protein structure prediction server allows protein models to be
built via homology modelling and/or ab initio modelling using
Rosetta (Kim et al., 2004; Raman et al., 2009; Song et al.,
2013). The derived protein models were structurally aligned
with the Leishmania donovani Nucleoside Transporter 1.1
(LdNT1.1) model built using Rosetta ab initio modelling soft-
ware published by Valdes et al. (2009; 2012). The authors of
these studies validated their model using site-directed
mutagenesis and kindly provided us with the co-ordinates of
their protein model. The TbAT1 model that gave the best
structural alignment with LdNT1.1 model was the top-ranked
model (model 1) suggested by ROBETTA and was chosen to
study the protein–ligand interactions in silico described in this
study. In order to create this protein model, the Ginzu Domain
Prediction in ROBETTA identified two domains of the TbAT1
that were modelled separately: (i) domain 1–267 with some
similarity to the structure of a bacterial fucose transporter [PDB
code: 3O7Q; (Dang et al., 2010)] and (ii) domain 268–463 with
some similarity with a bacterial glycerol-3-phosphate trans-
porter [PDB code: 1PW4 (Huang et al., 2003)]. These two
partial threaded protein models were assembled together as a
last step in ROBETTA. Molecular docking was performed
using FRED (McGann, 2012), a docking programme that uses
an exhaustive search algorithm and was used to dock mol-
ecules generated from a multiconformer database generated
using OMEGA. The docked poses were energy minimised
using SZYBKI (v 1.7.0 OpenEye Scientific Software, Santa Fe,
NM, USA) allowing partial relaxation of the protein residues in
the direct proximity to the ligand. FRED, OMEGA and SZYBKI
are software developed by OPENEYE (OpenEye Scientific
Software: Santa Fe, NM, USA).
Acknowledgements
This work was supported by the Wellcome Trust. The Well-
come Trust Centre for Molecular Parasitology is supported by
core funding from the Wellcome Trust (085349) and was
partly funded by a grant from the Medical Research Council
(G0701258). We gratefully acknowledge Ph.D. studentships
for D.N.A.T. (Wellcome Trust). A.A.E. (Commonwealth Office,
UK), A.A.M.A. (Aljouf University, Saudi Arabia) and K.J.A.
(Taif University, Saudi Arabia). A free academic license to
OpenEye Scientific Software available in the laboratory of
Michael Pollastri (Department of Chemistry and Chemical
Biology, Northeastern University) is gratefully acknowledged.
Prof Ujwal Shinde (Department of Biochemistry and Molecu-
lar Biology, Oregon Health and Science University) is particu-
larly acknowledged for providing the co-ordinates of the
LdNT1.1 protein model.
References
Al-Salabi, M.I., Wallace, L.J., Lüscher, A., Mäser, P.,
Candlish, D., Rodenko, B., et al. (2007) Molecular interac-
tions underlying the unusually high adenosine affinity of a
novel Trypanosoma brucei nucleoside transporter. Mol
Pharmacol 71: 921–929.
Alirol, E., Schrumpf, D., Amici Heradi, J., Riedel, A., de
Model of the Trypanosoma brucei AT1 transporter 897
© 2015 The Authors. Molecular Microbiology published by John Wiley & Sons Ltd., Molecular Microbiology, 96, 887–900
Patoul, C., Quere, M., and Chappuis, F. (2013) Nifurtimox-
eflornithine combination therapy for second-stage gambi-
ense human African trypanosomiasis: Medecins Sans
Frontieres experience in the Democratic Republic of the
Congo. Clin Infect Dis 56: 195–203.
Baker, N., Glover, L., Munday, J.C., Aguinaga Andres, D.,
Barrett, M.P., de Koning, H.P., and Horn, D. (2012) Aqua-
glyceroporin 2 controls susceptibility to melarsoprol and
pentamidine in African trypanosomes. Proc Natl Acad Sci
USA 109: 10996–11001.
Baker, N., de Koning, H.P., Mäser, P., and Horn, D. (2013)
Drug resistance in African trypanosomiasis: the melarso-
prol and pentamidine story. Trends Parasitol 29: 110–118.
Barrett, M.P., Vincent, I.M., Burchmore, R.J., Kazibwe, A.J.,
and Matovu, E. (2011) Drug resistance in human African
trypanosomiasis. Future Microbiol 6: 1037–1047.
Bernhard, S.C., Nerima, B., Mäser, P., and Brun, R. (2007)
Melarsoprol- and pentamidine-resistant Trypanosoma
brucei rhodesiense populations and their cross-resistance.
Int J Parasitol 37: 1443–1448.
Biebinger, S., Wirtz, L.E., Lorenz, P., and Clayton, C. (1997)
Vectors for inducible expression of toxic gene products in
bloodstream and procyclic Trypanosoma brucei. Mol
Biochem Parasitol 85: 99–112.
Bridges, D.J., Gould, M.K., Nerima, B., Mäser, P., Burchmore,
R.J., and de Koning, H.P. (2007) Loss of the high-affinity
pentamidine transporter is responsible for high levels of
cross-resistance between arsenical and diamidine drugs in
African trypanosomes. Mol Pharmacol 71: 1098–1108.
Brun, R., Schumacher, R., Schmid, C., Kunz, C., and Burri,
C. (2001) The phenomenon of treatment failures in human
African trypanosomiasis. Trop Med Int Health 6: 906–914.
Burkard, G., Fragoso, C.M., and Roditi, I. (2007) Highly effi-
cient stable transformation of bloodstream forms of Trypa-
nosoma brucei. Mol Biochem Parasitol 153: 220–223.
Carter, N.S., and Fairlamb, A.H. (1993) Arsenical-resistant
trypanosomes lack an unusual adenosine transporter.
Nature 361: 173–176.
Carter, N.S., Barrett, M.P., and de Koning, H.P. (1999) A drug
resistance determinant in Trypanosoma brucei. Trends
Microbiol 7: 469–471.
Christensen, J.J., Rytting, J.H., and Izatt, R.M. (1970) Ther-
modynamic pK, delta H-o, delta S-o, and delta Cp-o values
for proton dissociation from several purines and their
nucleosides in aqueous solution. Biochemistry 9: 4907–
4913.
Collar, C.J., Al-Salabi, M.I., Stewart, M.L., Barrett, M.P.,
Wilson, W.D., and de Koning, H.P. (2009) Predictive com-
putational models of substrate binding by a nucleoside
transporter. J Biol Chem 284: 34028–34035.
Dang, S., Sun, L., Huang, Y., Lu, F., Liu, Y., Gong, H., et al.
(2010) Structure of a fucose transporter in an outward-
open conformation. Nature 467: 734–738.
Delespaux, V., and de Koning, H.P. (2007) Drugs and drug
resistance in African trypanosomiasis. Drug Resist Updat
10: 30–50.
Gould, M.K., Vu, X.L., Seebeck, T., and de Koning, H.P.
(2008) Propidium iodide-based methods for monitoring
drug action in the kinetoplastidae: comparison with the
Alamar Blue assay. Anal Biochem 382: 87–93.
Gould, M.K., Bachmaier, S., Ali, J.A., Alsford, S., Tagoe,
D.N., Munday, J.C., et al. (2013) Cyclic AMP effectors in
African trypanosomes revealed by genome-scale RNA
interference library screening for resistance to the phos-
phodiesterase inhibitor CpdA. Antimicrob Agents Chem-
other 57: 4882–4893.
Graf, F.E., Ludin, P., Wenzler, T., Kaiser, M., Brun, R., Pyana,
P.P., et al. (2013) Aquaporin 2 mutations in Trypanosoma
brucei gambiense field isolates correlate with decreased
susceptibility to pentamidine and melarsoprol. PLoS Negl
Trop Dis 7: e2475.
Hirumi, H., and Hirumi, K. (1989) Continuous cultivation of
Trypanosoma brucei blood stream forms in a medium con-
taining a low concentration of serum protein without feeder
cell layers. J Parasitol 75: 985–989.
Holm, L., and Sander, C. (1996) Mapping the protein uni-
verse. Science 273: 595–603.
Holmes, P.H., Eisler, M.C., and Geerts, S. (2004) Current
chemotherapy of animal trypanosomiasis. In The Trypano-
somiases. Maudlin, I., Holmes, P.H., and Miles, M.A. (eds).
Wallingford, UK.: CABI Publishing, pp. 431–444.
Huang, Y., Lemieux, M.J., Song, J., Auer, M., and Wang, D.N.
(2003) Structure and mechanism of the glycerol-3-
phosphate transporter from Escherichia coli. Science 301:
616–620.
Kazibwe, A.J., Nerima, B., de Koning, H.P., Mäser, P., Barrett,
M.P., and Matovu, E. (2009) Genotypic status of the
TbAT1/P2 adenosine transporter of Trypanosoma brucei
gambiense isolates from Northwestern Uganda following
melarsoprol withdrawal. PLoS Negl Trop Dis 3: e523.
Kennedy, P.G. (2013) Clinical features, diagnosis, and treat-
ment of human African trypanosomiasis (sleeping sick-
ness). Lancet Neurol 12: 186–194.
Kim, D.E., Chivian, D., and Baker, D. (2004) Protein structure
prediction and analysis using the Robetta server. Nucleic
Acids Res 32: W526–W531.
de Koning, H.P. (2001a) Uptake of pentamidine in Trypano-
soma brucei brucei is mediated by three distinct transport-
ers: implications for cross-resistance with arsenicals. Mol
Pharmacol 59: 586–592.
de Koning, H.P. (2001b) Transporters in African trypano-
somes: role in drug action and resistance. Int J Parasitol
31: 512–522.
de Koning, H.P., and Jarvis, S.M. (1997a) Hypoxanthine
uptake through a purine-selective nucleobase transporter
in Trypanosoma brucei brucei procyclic cells is driven by
protonmotive force. Eur J Biochem 247: 1102–1110.
de Koning, H.P., and Jarvis, S.M. (1997b) Purine nucleobase
transport in bloodstream forms of Trypanosoma brucei is
mediated by two novel transporters. Mol Biochem Parasitol
89: 245–258.
de Koning, H.P., and Jarvis, S.M. (1999) Adenosine trans-
porters in bloodstream forms of Trypanosoma brucei
brucei: substrate recognition motifs and affinity for trypano-
cidal drugs. Mol Pharmacol 56: 1162–1170.
de Koning, H.P., Watson, C.J., and Jarvis, S.M. (1998) Char-
acterization of a nucleoside/proton symporter in procyclic
Trypanosoma brucei brucei. J Biol Chem 273: 9486–9494.
de Koning, H.P., Anderson, L.F., Stewart, M., Burchmore,
R.J., Wallace, L.J., and Barrett, M.P. (2004) The trypano-
cide diminazene aceturate is accumulated predominantly
through the TbAT1 purine transporter: additional insights
898 J. C. Munday et al. ■
© 2015 The Authors. Molecular Microbiology published by John Wiley & Sons Ltd., Molecular Microbiology, 96, 887–900
on diamidine resistance in African trypanosomes. Antimi-
crob Agents Chemother 48: 1515–1519.
de Koning, H.P., Bridges, D.J., and Burchmore, R.J. (2005)
Purine and pyrimidine transport in pathogenic protozoa:
from biology to therapy. FEMS Microbiol Rev 29: 987–
1020.
Legros, D., Evans, S., Maiso, F., Enyaru, J.C., and
Mbulamberi, D. (1999) Risk factors for treatment failure
after melarsoprol for Trypanosoma brucei gambiense
trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg
93: 439–442.
Linton, B., and Hamilton, A.D. (1999) Calorimetric investiga-
tion of guanidinium-carboxylate interactions. Tetrahedron
55: 6027–6038.
Lüscher, A., de Koning, H.P., and Mäser, P. (2007) Chemo-
therapeutic strategies against Trypanosoma brucei: drug
targets vs. drug targeting. Curr Pharm Des 13: 555–567.
McGann, M. (2012) FRED and HYBRID docking perfor-
mance on standardized datasets. J Comput Aided Mol Des
26: 897–906.
Major, D.T., Laxer, A., and Fischer, B. (2002) Protonation
studies of modified adenine and adenine nucleotides by
theoretical calculations and (15)N NMR. J Org Chem 67:
790–802.
Matovu, E., Geiser, F., Schneider, V., Mäser, P., Enyaru, J.C.,
Kaminsky, R., et al. (2001) Genetic variants of the TbAT1
adenosine transporter from African trypanosomes in
relapse infections following melarsoprol therapy. Mol
Biochem Parasitol 117: 73–81.
Matovu, E., Stewart, M.L., Geiser, F., Brun, R., Mäser, P.,
Wallace, L.J., et al. (2003) Mechanisms of arsenical and
diamidine uptake and resistance in Trypanosoma brucei.
Eukaryot Cell 2: 1003–1008.
Mäser, P., Sutterlin, C., Kralli, A., and Kaminsky, R. (1999) A
nucleoside transporter from Trypanosoma brucei involved
in drug resistance. Science 285: 242–244.
Mäser, P., Vogel, D., Schmid, C., Raz, B., and Kaminsky, R.
(2001) Identification and characterization of trypanocides
by functional expression of an adenosine transporter from
Trypanosoma brucei in yeast. J Mol Med (Berl) 79: 121–
127.
Moore, A., and Richer, M. (2001) Re-emergence of epidemic
sleeping sickness in southern Sudan. Trop Med Int Health
6: 342–347.
Mumba Ngoyi, D., Lejon, V., Pyana, P., Boelaert, M., Ilunga,
M., Menten, J., et al. (2010) How to shorten patient follow-up
after treatment for Trypanosoma brucei gambiense sleeping
sickness. J Infect Dis 201: 453–463.
Munday, J.C., Rojas Lopez, K.E., Eze, A.A., Delespaux, V.,
Van Den Abbeele, J., Rowan, T., et al. (2013) Functional
expression of TcoAT1 reveals it to be a P1-type nucleoside
transporter with no capacity for diminazene uptake. Int J
Parasitol Drugs Drug Resist 3: 69–76.
Munday, J.C., Eze, A.A., Baker, N., Glover, L., Clucas, C.,
Aguinaga Andres, D., et al. (2014) Trypanosoma brucei
aquaglyceroporin 2 is a high-affinity transporter for penta-
midine and melaminophenyl arsenic drugs and the main
genetic determinant of resistance to these drugs. J Antimi-
crob Chemother 69: 651–663.
Natto, M.J., Wallace, L.J., Candlish, D., Al-Salabi, M.I.,
Coutts, S.E., and de Koning, H.P. (2005) Trypanosoma
brucei: expression of multiple purine transporters prevents
the development of allopurinol resistance. Exp Parasitol
109: 80–86.
Nerima, B., Matovu, E., Lubega, G.W., and Enyaru, J.C.
(2007) Detection of mutant P2 adenosine transporter
(TbAT1) gene in Trypanosoma brucei gambiense isolates
from northwest Uganda using allele-specific polymerase
chain reaction. Trop Med Int Health 12: 1361–1368.
Priotto, G., Kasparian, S., Mutombo, W., Ngouama, D.,
Ghorashian, S., Arnold, U., et al. (2009) Nifurtimox-
eflornithine combination therapy for second-stage African
Trypanosoma brucei gambiense trypanosomiasis: a multi-
centre, randomised, phase III, non-inferiority trial. Lancet
374: 56–64.
Pyana Pati, P., Van Reet, N., Mumba Ngoyi, D., Ngay Lukusa,
I., Karhemere Bin Shamamba, S., and Büscher, P. (2014)
Melarsoprol sensitivity profile of Trypanosoma brucei gam-
biense Isolates from cured and relapsed sleeping sickness
patients from the Democratic Republic of the Congo. PLoS
Negl Trop Dis 8: e3212.
Raman, S., Vernon, R., Thompson, J., Tyka, M., Sadreyev,
R., Pei, J., et al. (2009) Structure prediction for CASP8 with
all-atom refinement using Rosetta. Proteins 77 (Suppl. 9):
89–99.
Räz, B., Iten, M., Grether-Buhler, Y., Kaminsky, R., and Brun,
R. (1997) The Alamar Blue assay to determine drug sen-
sitivity of African trypanosomes (T.b. rhodesiense and T.b.
gambiense) in vitro. Acta Trop 68: 139–147.
Richardson, J.S. (1981) The anatomy and taxonomy of
protein structure. Adv Protein Chem 34: 167–339.
Robays, J., Nyamowala, G., Sese, C., Betu Ku Mesu Kande,
V., Lutumba, P., Van der Veken, W., and Boelaert, M.
(2008) High failure rates of melarsoprol for sleeping sick-
ness, Democratic Republic of Congo. Emerg Infect Dis 14:
966–967.
Song, Y., DiMaio, F., Wang, R.Y., Kim, D., Miles, C., Brunette,
T., et al. (2013) High-resolution comparative modeling with
RosettaCM. Structure 21: 1735–1742.
Stanghellini, A., and Josenando, T. (2001) The situation of
sleeping sickness in Angola: a calamity. Trop Med Int
Health 6: 330–334.
Stewart, M.L., Burchmore, R.J., Clucas, C., Hertz-Fowler, C.,
Brooks, K., Tait, A., et al. (2010) Multiple genetic mecha-
nisms lead to loss of functional TbAT1 expression in drug-
resistant trypanosomes. Eukaryot Cell 9: 336–343.
Tatko, C.D., and Waters, M.L. (2004) Investigation of the
nature of the methionine-pi interaction in beta-hairpin
peptide model systems. Protein Sci 13: 2515–2522.
Teka, I.A., Kazibwe, A.J., El-Sabbagh, N., Al-Salabi, M.I.,
Ward, C.P., Eze, A.A., et al. (2011) The diamidine dimina-
zene aceturate is a substrate for the high-affinity pentami-
dine transporter: implications for the development of high
resistance levels in trypanosomes. Mol Pharmacol 80:
110–116.
Turecek, F., and Chen, X. (2005) Protonated adenine: tau-
tomers, solvated clusters, and dissociation mechanisms. J
Am Soc Mass Spectrom 16: 1713–1726.
Valdes, R., Arastu-Kapur, S., Landfear, S.M., and Shinde, U.
(2009) An ab initio structural model of a nucleoside per-
mease predicts functionally important residues. J Biol
Chem 284: 19067–19076.
Model of the Trypanosoma brucei AT1 transporter 899
© 2015 The Authors. Molecular Microbiology published by John Wiley & Sons Ltd., Molecular Microbiology, 96, 887–900
Valdes, R., Shinde, U., and Landfear, S.M. (2012) Cysteine
cross-linking defines the extracellular gate for the Leishma-
nia donovani nucleoside transporter 1.1 (LdNT1.1). J Biol
Chem 287: 44036–44045.
Vincent, I.M., Creek, D., Watson, D.G., Kamleh, M.A.,
Woods, D.J., Wong, P.E., et al. (2010) A molecular mecha-
nism for eflornithine resistance in African trypanosomes.
PLoS Pathog 6: e1001204.
Wallace, L.J., Candlish, D., and de Koning, H.P. (2002) Dif-
ferent substrate recognition motifs of human and trypano-
some nucleobase transporters. Selective uptake of purine
antimetabolites. J Biol Chem 277: 26149–26156.
Zimmer, S., and Biltonen, R. (1972) The thermodynamics of
proton dissociation of adenine. J Solution Chem 1: 291–
298.
Supporting information
Additional supporting information may be found in the online
version of this article at the publisher’s web-site.
900 J. C. Munday et al. ■
© 2015 The Authors. Molecular Microbiology published by John Wiley & Sons Ltd., Molecular Microbiology, 96, 887–900
